266 related articles for article (PubMed ID: 23573918)
1. Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease.
Martiskainen H; Haapasalo A; Kurkinen KM; Pihlajamäki J; Soininen H; Hiltunen M
Expert Opin Ther Targets; 2013 Jul; 17(7):781-94. PubMed ID: 23573918
[TBL] [Abstract][Full Text] [Related]
2. APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.
Tachibana M; Holm ML; Liu CC; Shinohara M; Aikawa T; Oue H; Yamazaki Y; Martens YA; Murray ME; Sullivan PM; Weyer K; Glerup S; Dickson DW; Bu G; Kanekiyo T
J Clin Invest; 2019 Mar; 129(3):1272-1277. PubMed ID: 30741718
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E increases cell association of amyloid-β 40 through heparan sulfate and LRP1 dependent pathways.
O'Callaghan P; Noborn F; Sehlin D; Li JP; Lannfelt L; Lindahl U; Zhang X
Amyloid; 2014 Jun; 21(2):76-87. PubMed ID: 24491019
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4.
Bilousova T; Melnik M; Miyoshi E; Gonzalez BL; Poon WW; Vinters HV; Miller CA; Corrada MM; Kawas C; Hatami A; Albay R; Glabe C; Gylys KH
Am J Pathol; 2019 Aug; 189(8):1621-1636. PubMed ID: 31108099
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
6. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.
Deane R; Sagare A; Hamm K; Parisi M; Lane S; Finn MB; Holtzman DM; Zlokovic BV
J Clin Invest; 2008 Dec; 118(12):4002-13. PubMed ID: 19033669
[TBL] [Abstract][Full Text] [Related]
7. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
Ma Q; Zhao Z; Sagare AP; Wu Y; Wang M; Owens NC; Verghese PB; Herz J; Holtzman DM; Zlokovic BV
Mol Neurodegener; 2018 Oct; 13(1):57. PubMed ID: 30340601
[TBL] [Abstract][Full Text] [Related]
8. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.
Bachmeier C; Paris D; Beaulieu-Abdelahad D; Mouzon B; Mullan M; Crawford F
Neurodegener Dis; 2013; 11(1):13-21. PubMed ID: 22572854
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
Donahue JE; Johanson CE
J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
[TBL] [Abstract][Full Text] [Related]
10. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V
FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538
[TBL] [Abstract][Full Text] [Related]
11. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier.
Pflanzner T; Janko MC; André-Dohmen B; Reuss S; Weggen S; Roebroek AJ; Kuhlmann CR; Pietrzik CU
Neurobiol Aging; 2011 Dec; 32(12):2323.e1-11. PubMed ID: 20630619
[TBL] [Abstract][Full Text] [Related]
12. Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.
Storck SE; Pietrzik CU
Pharm Res; 2017 Dec; 34(12):2637-2651. PubMed ID: 28948494
[TBL] [Abstract][Full Text] [Related]
13. The pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based therapeutic approaches.
Iurescia S; Fioretti D; Mangialasche F; Rinaldi M
J Alzheimers Dis; 2010; 21(1):35-48. PubMed ID: 20182014
[TBL] [Abstract][Full Text] [Related]
14. Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1.
Strickland MR; Holtzman DM
J Clin Invest; 2019 Mar; 129(3):969-971. PubMed ID: 30741722
[TBL] [Abstract][Full Text] [Related]
15. Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models.
Huang Y
Biochem Soc Trans; 2011 Aug; 39(4):924-32. PubMed ID: 21787325
[TBL] [Abstract][Full Text] [Related]
16. Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation.
Levi O; Dolev I; Belinson H; Michaelson DM
J Neurochem; 2007 Nov; 103(3):1031-40. PubMed ID: 17666042
[TBL] [Abstract][Full Text] [Related]
17. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.
Huang Y
Trends Mol Med; 2010 Jun; 16(6):287-94. PubMed ID: 20537952
[TBL] [Abstract][Full Text] [Related]
18. Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier.
Bachmeier C; Beaulieu-Abdelahad D; Mullan M; Paris D
Mol Cell Neurosci; 2013 Sep; 56():255-62. PubMed ID: 23831388
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E receptor pathways in Alzheimer disease.
Schmidt V; Carlo AS; Willnow TE
Wiley Interdiscip Rev Syst Biol Med; 2014; 6(3):255-70. PubMed ID: 24604742
[TBL] [Abstract][Full Text] [Related]
20. LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: relationship to cerebral amyloid angiopathy and APOE status.
Ruzali WA; Kehoe PG; Love S
Neurosci Lett; 2012 Sep; 525(2):123-8. PubMed ID: 22967844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
